DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This is a second Non-Final Office Action.
Election/Restrictions
Applicant's election of the following species in the reply filed on March 31, 2025 is acknowledged: 1) MELAS syndrome as the disease and 2) disulfiram as the compound. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)).
Applicant indicated claims 1-11 and 12-16 read on the elected species. The Examiner has determined claim 17 also reads on the elected species. Furthermore, claim 12 is a cancelled claim.
Claims 1, 2, 4-11 and 13-20 are pending and under consideration.
Claim Objections
The objection to claims 1 and 9 because of the term “disulfiram” should be replaced with “an effective amount of disulfiram,” is withdrawn based on the amendments.
Claim 9 is objected to because of the following informalities: the phrase “at a at a” should be replaced with “at a.” Appropriate correction is required.
Claim 11 is objected to because of the following informalities: the phrase “of-disulfurim” should be replaced with “of disulfurim.” Appropriate correction is required.
Claim Rejections - 35 USC § 112
The rejection of claims 1-11 and 13-17 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement, is withdrawn.
The rejection of claims 1-11 and 13-17 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for providing beneficial effects in the yeast mutated cell with the m.3243A>G mutation in mitochondrial DNA, ie. in the tRNALeu (UUR) (MTTL1) gene and the cybrid cells derived from patients with MELAS syndrome by improving mitochondrial respiration through the rescuing activity at specific concentrations, does not reasonably provide enablement for treating or preventing MELAS syndrome, is withdrawn.
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Claim Rejections - 35 USC § 102/103
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1, 2, 4-11 and 13-20 is/are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Cooper et al. (US 20100160428) as evidenced by Forsch et al. (Drug Res., 1976, 26(2), 173-177).
Cooper teaches the treatment of MELAS, see claim 26 on page 61, with N,N’-diethyldithiocarbamate (DDC), see claim 21 on page 60.
Forsch teaches DDC is a metabolite of disulfuram, and is therefore, inherently present upon administration of disulfuram.
The “reduced mitochondrial complex I and/or IV activity” is also inherent upon administration. Assuming, arguendo, the reduced complex occurs at specific concentrations, this would be obvious as a result-effective variable.
Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 105 USPQ 233, 235 (CCPA 1955). The adjustment of particular conventional working conditions (e.g., determining result effective amounts of the solvents taught by the cited references), is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. Accordingly, this type of modification would have been well within the purview of the skilled artisan and no more than an effort to optimize results.
Oral administration as a tablet is taught in claim 20, page 60. The daily administration is taught on page 43, paragraph 0393; the dosage amounts are found on pages 43-44, paragraphs 0393-0398. Determining dosing is considered routine and conventional, and, is considered a result-effective variables.
Claims 18 and 19 are drawn to wherein the subject exhibits at least one symptom of MELAS. The specification does not provide any rationale as to why a subject who is exhibiting a symptom of MELAS would be treated any differently than a subject who does not exhibit a symptom. Therefore, any subject identified with a known MELAS mutation may be treated the same, unless there is evidence to the contrary.
Thus, said claims are anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Cooper et al. (US 20100160428) as evidenced by Forsch et al. (Drug Res., 1976, 26(2), 173-177) since Cooper teaches the treatment of MELAS with DDC and Forsch teaches DDC is a metabolite of disulfiram.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached Monday - Friday, 10:00 am to 7:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SUSANNA MOORE/Primary Examiner, Art Unit 1624